Certain microRNAs in the saliva of concussion patients could help gauge the severity of concussions and predict the length of concussion symptoms.

Unexpected side effects have spelled the end for Ardelyx’s drug candidate to treat elevated potassium levels in the blood, which was in phase 3 testing.

The $17 million financing equips the lean French biotech to prepare its CTPS1 inhibitors for clinical testing in autoimmune disorders.

The enzyme PTK6 could be targeted to quell the growth of estrogen receptor-positive breast cancer, a common form of the disease.

LivaNova will sell its Cardiac Rhythm Management business to its joint venture partner, MicroPort Scientific.

Shares in DBV rose on the back of the data, going a little way to erasing the big drop it suffered after missing its primary efficacy endpoint.

Gamida Cell has named Julian Adams, Ph.D.—its current chair and chief scientific officer of Clal Biotech—as its new CEO.

Bayer has signed a potentially major research pact with Japan’s PeptiDream, marking the second big biobucks deal for the German pharma in the past week.